Tags

Type your tag names separated by a space and hit enter

A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease.
J Alzheimers Dis. 2017; 60(4):1365-1377.JA

Abstract

Alzheimer's disease (AD) is the most common type of age-related neurodegenerative disorder; nevertheless, nowadays there are no reliable biomarkers or non-invasive techniques available for its early detection. Recent studies have indicated that the circulating level profiles of microRNAs (miRNAs) have the potential to be used as valuable biomarkers for diagnosis, staging, and progress monitoring of various diseases. Here we report a novel 9-miRNA signature (hsa-miR-26a-5p, hsa-miR-181c-3p, hsa-miR-126-5p, hsa-miR-22-3p, hsa-miR-148b-5p, hsa-miR-106b-3p, hsa-miR-6119-5p, hsa-miR-1246, and hsa-miR-660-5p) that can be utilized as biomarker for detecting AD. We respectively profiled the serum miRNAs from 19 AD patients and 9 healthy control (HC) participants using the Next-Generation Sequencing (NGS). The NGS results were validated by quantitative real-time polymerase chain reaction (qRT-PCR) on a larger cohort of 121 AD and 86 HC cases. All the patients were divided into three groups (mild, moderate, and severe AD) based on the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR). Our research indicates that abnormal expression of distinct serum miRNAs occurs at different stages of AD. The difference of the area under the receiver operator characteristics curve (AUC) between the AD and the HC is between 70% and 85%. Among the 9 miRNAs, hsa-miR-22-3p has the best sensitivity (81.8%) and specificity (70.9%). The miRNA-panel is more valuable for AD diagnosis. The data suggest that the differentially expressed serum miRNAs could be used as biomarkers to improve the diagnosis of AD, particularly at the early stage, and to classify its clinical stages.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Neurology, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Quality Management, Blood Center of Shandong Province, Jinan, P. R. China.

Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Central Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, P. R. China.

MeSH

AgedAlzheimer DiseaseBiomarkersEarly DiagnosisFemaleHumansMaleMental Status and Dementia TestsMicroRNAsReal-Time Polymerase Chain ReactionRetrospective StudiesSensitivity and SpecificitySeverity of Illness Index

Pub Type(s)

Journal Article

Validation Study

Language

eng

PubMed ID

29036818

Citation

Guo, Rui, et al. "A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 60, no. 4, 2017, pp. 1365-1377.

Guo R, Fan G, Zhang J, et al. A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease. J Alzheimers Dis. 2017;60(4):1365-1377.

Guo, R., Fan, G., Zhang, J., Wu, C., Du, Y., Ye, H., Li, Z., Wang, L., Zhang, Z., Zhang, L., Zhao, Y., & Lu, Z. (2017). A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease : JAD, 60(4), 1365-1377. https://doi.org/10.3233/JAD-170343

Guo R, et al. A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease. J Alzheimers Dis. 2017;60(4):1365-1377. PubMed PMID: 29036818.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease. AU - Guo,Rui, AU - Fan,Gang, AU - Zhang,Jian, AU - Wu,Chunxiao, AU - Du,Yifeng, AU - Ye,Hui, AU - Li,Zhang, AU - Wang,Lili, AU - Zhang,Zhihui, AU - Zhang,Lu, AU - Zhao,Yueran, AU - Lu,Zhiming, PY - 2017/10/19/pubmed PY - 2018/7/24/medline PY - 2017/10/18/entrez KW - Alzheimer’s disease KW - biomarker KW - microRNAs KW - next-generation sequencing KW - quantitative Real-Time PCR KW - serum SP - 1365 EP - 1377 JF - Journal of Alzheimer's disease : JAD JO - J Alzheimers Dis VL - 60 IS - 4 N2 - Alzheimer's disease (AD) is the most common type of age-related neurodegenerative disorder; nevertheless, nowadays there are no reliable biomarkers or non-invasive techniques available for its early detection. Recent studies have indicated that the circulating level profiles of microRNAs (miRNAs) have the potential to be used as valuable biomarkers for diagnosis, staging, and progress monitoring of various diseases. Here we report a novel 9-miRNA signature (hsa-miR-26a-5p, hsa-miR-181c-3p, hsa-miR-126-5p, hsa-miR-22-3p, hsa-miR-148b-5p, hsa-miR-106b-3p, hsa-miR-6119-5p, hsa-miR-1246, and hsa-miR-660-5p) that can be utilized as biomarker for detecting AD. We respectively profiled the serum miRNAs from 19 AD patients and 9 healthy control (HC) participants using the Next-Generation Sequencing (NGS). The NGS results were validated by quantitative real-time polymerase chain reaction (qRT-PCR) on a larger cohort of 121 AD and 86 HC cases. All the patients were divided into three groups (mild, moderate, and severe AD) based on the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR). Our research indicates that abnormal expression of distinct serum miRNAs occurs at different stages of AD. The difference of the area under the receiver operator characteristics curve (AUC) between the AD and the HC is between 70% and 85%. Among the 9 miRNAs, hsa-miR-22-3p has the best sensitivity (81.8%) and specificity (70.9%). The miRNA-panel is more valuable for AD diagnosis. The data suggest that the differentially expressed serum miRNAs could be used as biomarkers to improve the diagnosis of AD, particularly at the early stage, and to classify its clinical stages. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/29036818/A_9_microRNA_Signature_in_Serum_Serves_as_a_Noninvasive_Biomarker_in_Early_Diagnosis_of_Alzheimer's_Disease_ DB - PRIME DP - Unbound Medicine ER -